Modified Calix[4]crowns as Molecular Receptors for Barium

Area of Science:

• Radiopharmaceutical Chemistry
• Supramolecular Chemistry
• Oncology

Background:

• Radiometal chelation is critical in radiopharmaceutical applications to prevent in vivo loss.
• Radium nuclides are promising for alpha-targeted cancer therapies.
• Current applications of radium-223 are limited to bone metastases.

Purpose of the Study:

• To develop novel chelators for stable group 2 metal binding, specifically barium and radium.
• To explore the potential of functionalized calix[4]crown-6 derivatives for radiopharmaceutical applications.
• To enable the use of radium for treating various cancer tissues beyond bone metastases.

Main Methods:

• Synthesis and testing of various functionalized calix[4]crown-6 derivatives.
• Evaluation of the binding stability of group 2 metals, using barium as a surrogate for radium.
• Assessment of the suitability of these chelators for in vivo radiopharmaceutical applications.

Main Results:

• Special functionalized calix[4]crown-6 derivatives demonstrate stable binding of group 2 metals like barium.
• The binding mode effectively prevents radiometal loss, crucial for minimizing background signals and off-target tissue damage.
• Barium-based calix[4]crowns show promise as surrogates for radium chelation.

Conclusions:

• Functionalized calix[4]crown-6 derivatives are effective chelators for group 2 metals.
• These chelators represent a significant advancement for in vivo radiometal retention in targeted therapies.
• The developed compounds hold potential for expanding the application of radium-based radiopharmaceuticals in cancer treatment.